Description

Technical Parameters

Bronchogen 20mg/bottle core introduction

Pharmaceutical-grade peptide formulation | Made in China bronchial repair and regeneration peptide 20mg/vial

Specifications : 20mg/bottle, 5 bottles/box

Purity : ≥99% (HPLC detection)

Appearance : White lyophilized powder

Storage : Store frozen at -20℃ away from light; after thawing, refrigerate at 2-8℃.

Core advantages and functions

Bronchogen is a synthetic peptide that targets airway repair and regeneration . By specifically regulating airway inflammatory responses, promoting epithelial repair, and improving lung function , it has significant application value in the treatment of chronic respiratory diseases, lung injury repair, and respiratory regenerative medicine. It is a key research tool in respiratory medicine research and translational medicine .

✅Bronchial repair mechanism :

Anti-inflammatory effects : Inhibits NF-κB and MAPK inflammatory signaling pathways

Epithelial repair : Promotes the proliferation and migration of airway epithelial cells

Mucus regulation : Regulates mucin secretion and ciliary clearance function.

Anti-fibrotic : Inhibits airway fibroblast transformation and collagen deposition

Immune regulation : regulating Th1/Th2 cell homeostasis and cytokine secretion

✅Quality advantages of Chinese manufacturers :

Sequence Design : Rational Design Based on Active Fragments of Respiratory Growth Factor

Synthesis process : Fmoc solid-phase synthesis combined with liquid-phase synthesis technology

Purification control : Preparative HPLC combined with ion-exchange chromatography, purity ≥ 99.5%.

Activity validation : Dual validation using an in vitro airway epithelial cell model and an in vivo lung injury model.

Aseptic production : Class C cleanroom, fully automated filling and freeze-drying system

Quality control documentation : Complete quality study documentation (CMC file package) + stability data

✅Product Features :

Airway targeting : has a special affinity for respiratory tissues

High stability : Enzyme stability is enhanced by D-amino acid and acetylation modification.

Good safety profile : Preclinical toxicology studies show a wide therapeutic window.

Synergistic effect : Can be used in combination with bronchodilators and glucocorticoids.

Usage and Storage Guide

1. Reconstitution and preparation :

Solvent selection :

First choice: Sterile saline

In vitro study: serum-free DMEM/F12 medium

Nebulization application: Sterile water for injection

Standard configuration :

Pour 2 mL of solvent into the 20 mg vial and gently swirl to dissolve.

A stock solution of 10 mg/mL was obtained .

Gradually dilute to the working concentration using the appropriate solvent.

Dissolution control :

Dissolution conditions: Dissolve at room temperature in the dark for 5-8 minutes.

Solution properties: Clear and transparent, without particles.

pH requirement: Final pH 6.8-7.4

Nebulizing solution: Dilute with physiological saline to 1-2 mg/mL before use.

2. Storage conditions :

Unopened :

Freeze at -20℃: Can be stored for 24 months

-80℃ deep freeze: can be stored for 36 months

Avoid repeated freeze-thaw cycles (≤3 times).

Reconstituted :

Stock solution: Stable for 5 days when refrigerated at 4°C.

Working solution: It is recommended to prepare and use immediately , and keep at 4°C for no more than 24 hours.

Nebulizing fluid: Use immediately after preparation.

Transportation conditions :

Dry ice transport (below -78℃)

Professional frozen transport packaging

Equipped with temperature recording equipment

Stability parameters :

Temperature sensitivity: Degradation is accelerated at temperatures above 37℃.

pH stability: 6.8-7.4 is optimal.

Photosensitivity: Sensitive to ultraviolet light

Oxidation sensitivity: Avoid contact with oxidants

3. Research and application plan :

In vitro cell experiments :

Cell model :

Human airway epithelial cells (16HBE, BEAS-2B)

Primary airway epithelial cells

Lung fibroblasts

alveolar macrophages

Concentration gradient :

Low concentration: 0.1-1 μg/mL

Medium concentration: 1-10 μg/mL

High concentration: 10-50 μg/mL

Processing time :

Acute effects: 1-6 hours (inflammatory factors)

Mid-term effect: 12-48 hours (gene repair)

Long-term effects: 72-120 hours (barrier function)

Evaluation indicators :

Cell viability: CCK-8, LDH release

Inflammatory factors: IL-6, IL-8, TNF-α

Barrier function: Transepithelial resistance (TEER)

Molecular mechanism: Western blot, immunofluorescence

Animal in vivo studies :

Disease model :

Asthma model: OVA sensitization and challenge

COPD model: Cigarette smoke exposure

Pulmonary fibrosis model: bleomycin induction

Acute lung injury model: LPS induction

Route of administration :

Nebulized inhalation: 1-2 mg/kg , once daily.

Intratracheal infusion: 0.5-1.0 mg/kg , once every other day.

Intraperitoneal injection: 0.2-0.5 mg/kg , once daily.

Intravenous injection: 0.1-0.3 mg/kg , once daily.

Dosage regimen :

Prophylactic administration: Begin 1 week before model establishment

Therapeutic administration: Begins after model establishment

Treatment duration: 7-28 days

Evaluation indicators :

Lung function: airway resistance, lung compliance

Inflammation assessment: BALF cell count, cytokines

Pathology: HE staining, Masson staining

Airway hyperresponsiveness: methacholine stimulation

Mechanism of action study :

Signaling pathways: NF-κB, MAPK, STAT

Oxidative stress: MDA, SOD, GSH

Apoptosis: TUNEL, Caspase-3

Autophagy regulation: LC3, p62

4. Experimental design optimization :

Dosage selection :

Low dose: 0.2 mg/kg

Medium dose: 1.0 mg/kg

High dose: 2.0 mg/kg

Control group setup :

Blank control: physiological saline

Model comparison: Disease model + solvent

Positive control: Dexamethasone (1 mg/kg)

Time point design :

Acute phase: 6-72 hours after administration

Subacute phase: 1-2 weeks

Chronic phase: 2-4 weeks

Sample collection :

BALF: Bronchoalveolar Lavage Fluid

Lung tissue: fixed with 4% paraformaldehyde/flash-frozen in liquid nitrogen

Serum: Store at -80℃ after separation.

Detection method :

Lung function test

Histopathological score

Immunohistochemical analysis

Molecular biological detection

Why choose Bronchogen, made in China?

Technical advantages :

Autonomous design capability of respiratory system-targeting peptides

Advanced atomized formulation technology

A comprehensive respiratory disease model platform

Professional pharmacokinetic studies

Quality Guarantee :

Strict raw material and process control

Advanced analytical and testing equipment

Complete stability study

High consistency between batches

Service Support :

Professional technical support team

Detailed application solution guidance

Literature support and research consultation

Customized peptide modification services

Cost -effectiveness :

Large-scale production reduces costs

Compared to imported products, they have a clear price advantage.

Flexible packaging options

Summarize

Bronchogen represents China's technological advancement in the research of therapeutic peptides for respiratory diseases . Through innovative sequence design, rigorous manufacturing processes, and systematic pharmacological validation , it provides a high-quality, highly active research tool for respiratory medicine research worldwide . This product has significant application value in the study of respiratory disease mechanisms and drug development , contributing to the advancement of the field of respiratory medicine.

Need anything, please contact us